Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Stanford Univ

Neither a doctor nor a teaching hospital

Research payments

$2,178,377

171 payments

Through program year 2025, Stanford Univ is reported as receiving $2,178,377 in research payments, across 171 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $82,829 18
2024 Research $518,734 42
2023 Research $456,506 43
2022 Research $89,900 11
2021 Research $233,905 16
2020 Research $192,261 6
2019 Research $604,242 35

Breakdown

Who paid Research payments · program years 2019–2025
  1. Janssen Research & Development, LLC $931,127 107 payments
  2. AstraZeneca Pharmaceuticals LP $585,459 13 payments
  3. TESARO, Inc. $214,099 3 payments
  4. Acerta Pharma LLC $155,108 4 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $128,596 3 payments
  6. Siemens Medical Solutions USA, Inc. $100,000 3 payments
  7. AstraZeneca UK Limited $33,347 5 payments
  8. Alexion Pharmaceuticals, Inc. $29,464 1 payment
  9. Daiichi Sankyo Inc. $1,177 32 payments
Studies the money was for Research payments · program years 2019–2025
  1. Noprodvir0001 $477,427 24 payments
  2. A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder $380,608 42 payments
  3. Neoadjuvant Durvalumab and chemotherapy in variant histology Muscle Invasive bladder Cancer $245,159 2 payments
  4. Phase 2 Multicohort Study to Evaluate the Safety and Efficacy of Novel Treatment Combinations in Patients With Recurrent Ovarian Cancer Opal $214,099 3 payments
  5. Adjuvant Durvalumab for Early Stage Non-Small Cell Lung Cancer Patients with ctDNA Minimal Residual Disease $190,797 2 payments
  6. A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia $121,388 2 payments
  7. Title not available in IMPACT or MLCS description not available at AZ Clinical Trials $89,280 1 payment
  8. The Feasibility of Telehealth-Based Palliative Care Intervention and Digital Symptom Monitoring on Patients diagnosed with AML $50,000 1 payment
  9. A Phase 3b Multi Center Open label PCI32765 Ibrutinib Long term Extension Study $36,320 26 payments
  10. A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer $32,593 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record